News & Events about Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE Get Rating) saw some unusual options trading on Wednesday. Traders purchased 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average volume of 165 put options. Xenon Pharmaceuticals Trading Up 1.2 % NASDAQ ...
Xenon Pharmaceuticals (NASDAQ:XENE Get Rating)s stock had its outperform rating reissued by analysts at Royal Bank of Canada in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $51.00 price objective on the ...
Xenon Pharmaceuticals (NASDAQ:XENE Get Rating) had its price objective lifted by Royal Bank of Canada from $49.00 to $51.00 in a research report report published on Tuesday , Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical companys ...
XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026 BURNABY, British Columbia, Jan. 09, 2023 (GLOBE ...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE Get Rating) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical volume of 165 put options. Analyst Upgrades and ...